These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9595983)

  • 1. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease.
    Högl BE; Gómez-Arévalo G; García S; Scipioni O; Rubio M; Blanco M; Gershanik OS
    Neurology; 1998 May; 50(5):1332-9. PubMed ID: 9595983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective perception of sleep benefit in Parkinson's disease: Valid or irrelevant?
    Lee W; Evans A; Williams DR
    Parkinsonism Relat Disord; 2017 Sep; 42():90-94. PubMed ID: 28688983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.
    Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P
    Clin Neuropharmacol; 2000; 23(1):28-33. PubMed ID: 10682228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
    Romigi A; Stanzione P; Marciani MG; Izzi F; Placidi F; Cervellino A; Giacomini P; Brusa L; Grossi K; Pierantozzi M
    J Neural Transm (Vienna); 2006 Dec; 113(12):1909-13. PubMed ID: 16736238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
    Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N
    Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
    Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
    Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
    Bosco D; Plastino M; Bosco F; Fava A; Rotondo A
    Minerva Med; 2011 Apr; 102(2):125-32. PubMed ID: 21483399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pain Correlates with Sleep Disturbances in Parkinson's Disease Patients.
    Fu YT; Mao CJ; Ma LJ; Zhang HJ; Wang Y; Li J; Huang JY; Liu JY; Liu CF
    Pain Pract; 2018 Jan; 18(1):29-37. PubMed ID: 28371220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time structure of leg movement activity during sleep in untreated Parkinson disease and effects of dopaminergic treatment.
    Puligheddu M; Figorilli M; Aricò D; Raggi A; Marrosu F; Ferri R
    Sleep Med; 2014 Jul; 15(7):816-24. PubMed ID: 24891077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.
    Bliwise DL; Trotti LM; Wilson AG; Greer SA; Wood-Siverio C; Juncos JJ; Factor SA; Freeman A; Rye DB
    Mov Disord; 2012 Aug; 27(9):1118-24. PubMed ID: 22753297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.